Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 523 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Diseases, Viral Clear all
Completed Phase 2 Interventional Results available

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

NCT04160065
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

NCT00297011
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir+clobetasol gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Herpevac Neonatal Substudy

NCT00138320
View directory record Official record
Conditions
Herpes Simplex
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

NCT02059499
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions
imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Melanoma

NCT00003556
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

NCT02730312
View directory record Official record
Conditions
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
Interventions
XmAb14045
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Jacksonville, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

NCT00698568
View directory record Official record
Conditions
Prophylaxis for Herpes Simplex
Interventions
Herpes simplex candidate vaccine- adjuvanted GSK 208141, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
7,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1999
U.S. locations
36
States / cities
La Jolla, California • Middle Valley, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NCT00002185
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

NCT00000985
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Vidarabine, Acyclovir, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

NCT06887348
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
Observational study with no interventions
Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984
View directory record Official record
Conditions
Sarcoma
Interventions
nicotine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 78 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 23, 2026, 9:03 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Antiviral Prophylaxis in a Burn Population

NCT02349828
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
24 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

NCT02798419
View directory record Official record
Conditions
Common Warts
Interventions
DFD05 Cream, Active01 Cream
Drug
Lead sponsor
Dr. Reddys Laboratories, SA
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

NCT00002116
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:03 PM EDT
Completed No phase listed Observational

Advanced Endoscopy During COVID-19

NCT04385147
View directory record Official record
Conditions
Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer, COVID-19, SARS-CoV-2
Interventions
Endoscopic management according to standard of care
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
Not listed
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 23, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
VCL-HB01, VCL-HM01, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 9:03 PM EDT